文献速递炎症性肠病

维得利珠单抗在炎症性肠病中暴露-效应关系的真实世界多中心观察性研究及群体药代动力学建模:ERELATE研究

Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study.
PubMed 文献 · Aliment Pharmacol Ther · 2022-04-27

ERELATE是一项4期多国回顾性观察研究,纳入6国9中心695例接受静脉维得利珠单抗的溃疡性结肠炎或克罗恩病成人患者,随访52周。采用群体药代动力学模型预测暴露,发现早期谷浓度较高与后续临床缓解相关,第6周谷浓度≥31.0和≥32.0 μg/ml分别与第14周和第52周临床缓解相关;基线清除率是唯一预测第52周临床和深度缓解的暴露指标。

要点

  • 第14周时临床、内镜、深度和生物学缓解率分别为47.3%、59.6%、30.7%和19.0%。
  • 第6周谷浓度≥31.0 μg/ml与第14周临床缓解相关,≥32.0 μg/ml与第52周临床缓解相关。
  • 多变量分析显示基线清除率是唯一预测第52周临床和深度缓解的暴露指标。

核心结论

  • 在这项真实世界研究中,维得利珠单抗观察到正向的暴露-效应关系;诱导期药物浓度可能是短期和长期结局的重要预测因素,基线清除率也可能是缓解的重要预测因素。

研究设计与样本

  • ERELATE为4期、多国、回顾性、观察性研究,收集6国9中心接受静脉维得利珠单抗治疗的溃疡性结肠炎或克罗恩病成人患者真实世界数据,随访52周。
  • 研究共纳入695例患者,其中溃疡性结肠炎304例、克罗恩病391例;中位年龄39岁,男性占47.9%,86.9%有既往肿瘤坏死因子拮抗剂暴露史。
  • 采用已建立的群体药代动力学模型(基于贝叶斯方法纳入 observed 维得利珠单抗浓度)预测个体暴露,评估暴露-效应关系。

主要发现

  • 第14周时,临床缓解、内镜缓解、深度缓解(临床加内镜)和生物学缓解率分别为47.3%、59.6%、30.7%和19.0%。
  • 治疗早期较高的维得利珠单抗谷浓度与后续时间点的临床缓解持续相关。
  • 第14周临床缓解与第6周谷浓度≥31.0 μg/ml相关,第52周临床缓解与第6周谷浓度≥32.0 μg/ml相关。
  • 多变量分析识别基线清除率为唯一预测第52周临床和深度缓解的暴露指标。

关键数值与推荐

  • 第14周临床缓解定义为第6周谷浓度≥31.0 μg/ml。
  • 第52周临床缓解定义为第6周谷浓度≥32.0 μg/ml。
  • 基线清除率是唯一预测第52周临床和深度缓解的暴露指标。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ERELATE was a phase 4, multinational, retrospective, observational study. AIM: To evaluate the relationship between intravenous vedolizumab exposure and treatment outcomes over 52 weeks in adults with ulcerative colitis (UC) or Crohn's disease (CD). METHODS: Real-world data from patients with UC or CD treated with intravenous vedolizumab in nine centres in six countries were collected retrospectively. Treatment outcomes were collected at Weeks 14, 26 and 52. An established population pharmacokinetic model (incorporating observed vedolizumab concentrations based on a Bayesian approach) was used to predict individual vedolizumab exposure. Vedolizumab exposure-response relationship was evaluated overall, by indication and based on baseline characteristics. RESULTS: The study population (n = 695; UC, n = 304; CD, n = 391) had a median age of 39 years; 47.9% were male and 86.9% had prior tumour necrosis factor antagonist exposure. By Week 14, clinical, endoscopic, deep (clinical plus endoscopic) and biologic remission was achieved by 47.3%, 59.6%, 30.7% and 19.0% of patients respectively. Higher vedolizumab trough concentration early in treatment was consistently associated with clinical remission at later time points. Clinical remission at Week 14 and Week 52 was associated with Week 6 trough concentrations of ≥31.0 and ≥32.0 μg/ml respectively. Importantly, multivariable analysis identified baseline clearance as the only exposure measure predictive of clinical and deep remission at Week 52. CONCLUSIONS: In this real-world study, a positive exposure-response relationship was observed for vedolizumab. Vedolizumab concentration during induction may be an important predictor of short- and long-term outcomes, and similarly, vedolizumab baseline clearance may be an important predictor of remission.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Vande Casteele N, Sandborn WJ, Feagan BG, et al. Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study. Aliment Pharmacol Ther. 2022. PMID: 35474325. doi:10.1111/apt.16937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。